검색
Biodexa Pharmaceuticals PLC
BDRX관심 목록에 추가
2.940USD
-0.060-2.00%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
1.33M시가총액
16.87P/E TTM
자세한 내용은 Biodexa Pharmaceuticals PLC 회사
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLC 정보
종목 코드 BDRX
회사 이름Biodexa Pharmaceuticals PLC
상장일Dec 08, 2014
CEOStamp (Stephen A)
직원 수- -
유형Depository Receipt
회계 연도 종료Dec 08
주소1 Caspian Point
도시ABINGDON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United Kingdom
우편 번호CF10 4DQ
전화4401235888300
웹사이트https://www.biodexapharma.com/
종목 코드 BDRX
상장일Dec 08, 2014
CEOStamp (Stephen A)
Biodexa Pharmaceuticals PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
자주 묻는 질문
Biodexa Pharmaceuticals PLC의 상위 5대 주주는 누구인가요?
Biodexa Pharmaceuticals PLC의 상위 5대 주주는 다음과 같습니다: Dr. Simon Turton
Biodexa Pharmaceuticals PLC(BDRX)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Biodexa Pharmaceuticals PLC의 주식을 보유한 기관은 총 26곳이며, 이들이 보유한 주식의 총 가치는 약 66.51K로 전체 발행 주식의 7.79%를 차지합니다. 이는 2025Q4 대비 60313.00 증가한 수치입니다.